Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Election of Directors
Director Nominees |
|
|
||
|
|
|
|
|
|
6,490,732 |
109,026 |
98.3% |
1.7% |
|
6,508,888 |
90,870 |
98.6% |
1.4% |
|
6,533,190 |
66,568 |
99.0% |
1.0% |
|
6,541,297 |
58,461 |
99.1% |
0.9% |
|
6,590,211 |
9,547 |
99.9% |
0.1% |
Reappointment of External Auditors
Outcome |
|
|
||
|
|
|
|
|
|
7,212,551 |
148,556 |
98.0% |
2.0% |
Approval of the Continuation of Crescita’s Share Incentive Plan
Outcome |
|
|
||
|
|
|
|
|
Share Incentive Plan approved |
6,526,477 |
73,281 |
98.9% |
1.1% |
About
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606355142/en/
Vice-President, Reporting and Corporate Affairs
Email:lkisa@crescitatx.com
Source: